Edition:
India

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

1.65USD
15 Dec 2017
Change (% chg)

$0.06 (+3.77%)
Prev Close
$1.59
Open
$1.60
Day's High
$1.69
Day's Low
$1.60
Volume
29,566
Avg. Vol
279,064
52-wk High
$4.25
52-wk Low
$0.63

Chart for

About

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the... (more)

Overall

Beta: -2.65
Market Cap(Mil.): $67.20
Shares Outstanding(Mil.): 23.50
Dividend: --
Yield (%): --

Financials

BRIEF-Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002

* CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002

29 Nov 2017

BRIEF-Capricor Therapeutics reports Q3 loss per share $0.12

* Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program

09 Nov 2017

BRIEF-Capricor says results from Duchenne muscular dystrophy trial to be presented at AHA late-breaking session

* Capricor announces 12-month results from HOPE-1 trial in Duchenne muscular dystrophy to be presented at AHA late-breaking session Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Capricor Therapeutics ‍enters into common stock sales agreement

* Capricor Therapeutics - ‍entered into common stock sales agreement - sec filing

20 Oct 2017

BRIEF-Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy

* Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy with naming of principal investigator

26 Sep 2017

BRIEF-Capricor to present 6-month results from the randomized hope trial of CAP-1002

* Capricor Therapeutics to present six-month results from the randomized hope trial of CAP-1002 in duchenne muscular dystrophy in a late breaking session of the world muscle society Source text for Eikon: Further company coverage:

18 Sep 2017

BRIEF-Capricor Therapeutics Q2 loss per share $0.16

* Capricor Therapeutics reports second quarter 2017 financial results and provides corporate update

11 Aug 2017

BRIEF-Capricor Therapeutics retains full rights to CAP-1002 as Janssen Biotech decides not to exercise option

* Capricor therapeutics- no payments between capricor and janssen are required to be made in relation to this decision

07 Jul 2017

Earnings vs. Estimates